Pharmacology of AMG 416 (Velcalcetide), a Novel Peptide Agonist of the Calcium-Sensing Receptor, for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients

Pharmacology of AMG 416 (Velcalcetide), a Novel Peptide Agonist of the Calcium-Sensing Receptor, for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients

GPCR Target: hCaSR

Authors: Sarah Walter, et al.

Company: Amgen, Inc.

Journal: Journal of Pharmacology and Experimental Therapeutics August 2013, 346 (2) 229-240

Year Published: 2013

Tags:

Leave a Reply